Receptor for activated C kinase 1 (RACK1) is associated with certain aspects of cancer biology and signaling pathways, but its function in pancreatic ductal adenocarcinoma (PDAC) remains unknown. In the present study, 157 patients with PDAC were enrolled. RACK1 mRNA and protein expression levels were analyzed in PDAC tissues and matched adjacent noncancerous tissues by reverse transcription-quantitative polymerase chain reaction and western blotting. RACK1 expression levels in paraffin-embedded PDAC tissues were determined by immunohistochemistry. The associations between RACK1 expression and clinical data were evaluated using χ 2 analysis. The relationship between RACK1 expression and the survival data of patients was analyzed using Kaplan-Meier and log rank tests. RACK1 mRNA and protein were revealed to be overexpressed in PDAC tumor tissues compared with adjacent noncancerous tissues. RACK1 expression was associated with clinical stage (P=0.001), lymph node invasion (P=0.003) and liver metastasis (P=0.001). Furthermore, patients with PDAC and high RACK1 expression demonstrated shorter overall survival times compared with patients with low RACK1 expression (P=0.002). Multivariate analysis indicated that RACK1 overexpression was an independent prognostic factor for patients with PDAC. Overexpression of RACK1 may contribute to tumor progression, and may be a potential prognostic biomarker for patients with PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a serious disease with the lowest five-year survival rate among all solid cancers (<5%) (1) . At present, PDAC is the fourth leading cause of cancer-associated mortality in the USA and its incidence has increased in past decades (2) . Poor survival is probably due to early local invasion and metastasis, which means that potentially curative surgery is no longer an option for 85% of patients at the point of diagnosis (3) . Furthermore, patients who have undergone surgery may experience local recurrence or metastasis within 1 year (4). Therefore, an improved understanding of the biological processes underlying PDAC, in particular the aggressive nature of its invasion, is warranted.
Receptor for activated C kinase 1 (RACK1), also known as GNB2L1, is a 36-kilodalton cytosolic protein (5) . It was first reported as an anchoring protein with seven WD40 (Trp-Asp) repeats (6) . RACK1 has been revealed to interact with multiple signaling molecules, including protein kinase C (PKC), period circadian clock 1 and Src (7, 8) . It is regarded as a platform for various signal transduction pathways. RACK1 is involved in cell division, invasion and migration in cancer (5, 9, 10) . However, the function of RACK1 in pancreatic ductal adenocarcinoma has not yet been investigated.
The aim of the present study was to assess the expression of RACK1 in PDAC tumor tissues and adjacent noncancerous tissues, and to compare RACK1 expression with clinicopathological characteristics. The value of RACK1 as a prognostic biomarker for patients with PDAC was then evaluated. 
Materials and methods

Patients
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA from 8 randomly selected primary tumor and adjacent non-tumor tissue samples were extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. RNA (2 µg) from each sample was used for complementary DNA synthesis using the Primescript RT reagent kit (Takara Biotechnology Co., Ltd., Dailan, China). To amplify the spliced form of human RACK1, the following primer sequences were used: forward, 5'-GAT TCT GGA AAT ATT GAC TCT T-3' and reverse, 5'-AAC TGG GCC CTT CTG GGT AGA C-3'. GAPDH was used as an internal control and the primer sequences were as follows: forward, 5'-GCA CCG TCA AGG CTG AGA AC-3' and reverse, 5'-TGG TGA AGA CGC CAG TGG A-3'. PCR was performed on the ABI prism 7500 sequence detection system (Applied Biosystems; Thermo Fisher Scientific, Inc., USA) and using SYBR Green PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific, Inc., USA), the thermocycler conditions were as follows: 50˚C for 2 min and 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min. The relative expression levels of RACK1 was normalized to that of GAPDH using the comparative 2 -ΔΔCq method (12) .
Western blotting. The 8 tumor samples which was selected for RT-qPCR were homogenized in ice-cold radio immunoprecipitation assay lysis buffer at 4˚C for 15 min (cat. no. 9806; Cell Signaling Technology, Inc., Danvers, MA, USA) and centrifuged at 13,400 x g at 4˚C for 20 min. Then protein concentrations were determined using a Bio-Rad BCA assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Next, equal amounts of 5X Laemmli buffer was added and the protein was boiled. 50 µg proteins were resolved in 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked for 1 h in 5% bovine milk diluted in TBST at room temperature and incubated with the following antibodies: RACK1 (cat. no. ab72483; 1:500; Abcam, Cambridge, UK) and GAPDH (cat. no. SAB1405848; 1:1,000; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at room temperature for 2 h. Following washing with TBST (0.05% Tween20) three times, the membranes were subsequently incubated with corresponding horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin G (IgG) (cat. 
Results
RACK1 protein is overexpressed in patients with PDAC.
RACK1 mRNA and protein expression levels were assessed by RT-qPCR and western blotting. Of the 8 randomly selected cases, RACK1 mRNA and protein were overexpressed in 7 out of 8 PDAC tumor specimens compared with in adjacent noncancerous tissues (ANT; Figs. 1 and 2 ). The medians of RACK1 mRNA and protein expression increased by 2.12 fold and 3.43 fold, respectively (relative ratio of tumor/ANT). In addition, immunohistochemistry confirmed that RACK1 protein was overexpressed in the 121 PDAC lesions compared with their matched adjacent noncancerous tissues (Fig. 3) . Furthermore, the IHC data revealed that RACK1 was primarily localized in the cytoplasm of the PDAC cancer cells. No positive staining was identified in the stroma tissues of the tumor (Fig. 3) .
RACK1 expression is associated with clinical data in patients with PDAC.
The immumohistochemical staining data suggested an increase in the proportion of RACK1 in PDAC tumor tissues compared with adjacent noncancerous tissues. A total of 121/157 (59.2%) of the PDAC cases exhibited high expression levels of RACK1 (SI ≥6), whereas 36/157 (40.8%) had low levels of RACK1 (IS <6). The relationships between RACK1 expression and clinicopathological features are summarized in Table II . The results indicated that RACK1 expression was significantly associated with histological differentiation (P<0.001), lymph node invasion (P<0.001) and clinical stage (P=0.011). However, no associations were observed between RACK1 expression and age, sex, tumor location or tumor size.
Association between RACK1 expression and prognosis in patients with PDAC. To determine whether RACK1
expression is a prognostic factor for patients with PDAC, Kaplan-Meier analysis and log-rank tests were performed using RACK1 protein expression and clinical follow-up data in all 157 patients. A total of 147 patients died during the follow-up period, and 10 patients were still alive. The results indicated that the median survival time in patients with high RACK1 expression (14.3±1.6 months; n=121) was significantly shorter compared with in patients with a low RACK1 expression (26.9±3.2 months; n=36; P<0.0001; Fig. 4A ). These results revealed that high level of RACK1 expression indicates poor prognosis for patients with PDAC. Overall survival time was also examined in subgroups of patients. Patients with PDAC in the high RACK1 expression group with early (I and II) and advanced stage (III and IV) PDAC had significantly shorter overall survival times than those in the low RACK1 expression group (P= 0.0046 and P<0.001, respectively; Fig. 4B and C, respectively). In addition, univariate and multivariate analyses revealed that RACK1 expression, histological differentiation, lymph node invasion and tumor resectability were all independent prognostic factors in patients with PDAC (Table III) .
Discussion
Pancreatic ductal adenocarcinoma is known for its poor prognosis (13) . The aggressive nature of its invasion, high incidence of early recurrence and poor response to radiotherapy and chemotherapy all contribute to the poor outcomes observed in patients with PDAC (14) . To the best of our knowledge, the association between RACK1 expression and prognosis in PDAC was not reported prior to the present study, where RACK1 expression was examined in PDAC in detail.
In the present study, RACK1 expression was revealed to be dramatically higher in PDAC tumor tissues than in adjacent noncancerous tissues. RACK1 expression was associated with T classification, N classification, clinical stage and liver metastasis, indicating that RACK1 may be a potential biomarker for patients with metastasis. Furthermore, the results of the present study revealed that patients with high RACK1 expression had shorter overall survival times than those with low RACK1 expression. Multivariate analysis revealed that RACK1 expression level was an independent prognostic factor for patients with PDAC. These results suggested that RACK1 was involved in PDAC progression and may be a novel prognostic biomarker for PDAC. have also been demonstrated to be correlated with outcome in patients with PDAC (18) (19) (20) . However, the efficacy of such prognostic markers in clinical application remains unknown. Therefore, further investigation is warranted to discover novel Table II . Relationship between RACK1 protein expression levels in pancreatic ductal adenocarcinoma and clinical pathological features (n=157). prognostic markers with improved prognostic efficacy in patients with PDAC. RACK1, which is upregulated in several solid malignancies, was originally reported in colorectal cancer (21) . RACK1 serves as a scaffold and anchoring protein for PKC, and stabilizes the activated conformation of PKC. RACK1 has been associated with several signaling pathways, and serves a vital function in tumorigenesis (22) . RACK1 was reported to be overexpressed in multiple cancers including melanoma (23), gastric cancer (24), hepatocellular carcinoma (25) and pulmonary adenocarcinoma (26) . RACK1 is thought to promote tumor invasion and metastasis. However, RACK1 also suppresses tumor growth in gastric cancer, indicating that RACK1 may serve different functions in different tumors. . Kaplan-Meier curves of survival differences among patients with PDAC with (A) high RACK1 expression (n=121) and low RACK1 expression (n=36), and patients with PDAC in the high and low RACK1 expression groups with (B) early (I and II) and (C) advanced stage (III and IV) PDAC. P-values were determined using the log-rank test. PDAC, pancreatic ductal adenocarcinoma; RACK1, receptor for activated C kinase 1; OS, overall survival. Table III . Univariate and multivariate analysis of prognostic parameters for survival in patients with pancreatic ductal adenocarcinoma.
Univariate analysis
Multivariate analysis Mamidipudi and Cartwright (27) reported that RACK1 inhibited colorectal cancer cell proliferation via the regulation of Src activity. However, Saito et al (28) reported that RACK1 was overexpressed in colon cancer, and promoted colon cancer cell proliferation. Thus, the function of RACK1 varies between tumor types, and remains to be elucidated. The present study measured RACK1 mRNA and protein expression levels in tumor tissues and adjacent noncancerous tissues from 157 patients with PDAC. The results revealed that RACK1 was overexpressed in tumor tissues compared with adjacent noncancerous tissues. RACK1 was associated with clinical stage, differentiation and lymph node metastasis in patients with PDAC.
In conclusion, RACK1 was overexpressed in patients with PDAC, and positively associated with the degree of malignancy in patients with PDAC. Therefore, RACK1 may serve as a novel biomarker and potential therapeutic target. Further investigations, in particular those concerning the molecular mechanisms underlying the effect of RACK1 in PDAC, are being performed.
